SlideShare une entreprise Scribd logo
1  sur  6
Télécharger pour lire hors ligne
 
 
Persistent Systems 
Soft performance, Margin headwinds limit near term upside
July 28, 2014 
Prabhudas Lilladher Pvt. Ltd. and/or its associates (the 'Firm') does and/or seeks to do business with companies covered in its research reports. As a result investors should be aware that 
the Firm may have a conflict of interest that could affect the objectivity of the report. Investors should consider this report as only a single factor in making their investment decision. 
Please refer to important disclosures and disclaimers at the end of the report 
 
Q1FY15 Result Update 
Shashi Bhusan 
shashibhusan@plindia.com 
+91‐22‐66322300 
Hussain Kagzi 
hussainkagzi@plindia.com 
+91‐22‐66322242 
Rating  Accumlate 
Price  Rs1,284 
Target Price  Rs1,285 
Implied Upside   .1% 
Sensex   26,127 
Nifty  7,790 
(Prices as on July 25, 2014) 
Trading data 
Market Cap. (Rs bn)  51.4 
Shares o/s (m)  40.0 
3M Avg. Daily value (Rs m)  222.4 
Major shareholders 
Promoters   38.96% 
Foreign   27.37% 
Domestic Inst.  9.82% 
Public & Other   23.85% 
Stock Performance 
 (%)  1M  6M  12M 
Absolute  16.0  27.4  138.8 
Relative   12.8  3.7  106.9 
How we differ from Consensus 
EPS (Rs)  PL  Cons.  % Diff. 
2015  78.6  77.7  1.2 
2016  94.2  90.8  3.8 
 
Price Performance (RIC: PERS.BO, BB: PSYS IN) 
 
Source: Bloomberg 
0
200
400
600
800
1,000
1,200
1,400
1,600
Jul‐13
Sep‐13
Nov‐13
Jan‐14
Mar‐14
May‐14
Jul‐14
(Rs)
Persistent Systems’ (Persistent’s) Q1FY15 result was another soft quarter compared 
to  PLe/Consensus’  expectation.  We  see  weak  start  to  the  year  and  near  term 
headwinds to operating margin to restrict upside. Retain “Accumulate”.  
 Revenue  and  margin  softer  than  expected:  Persistent’s  Q1FY15  result  was 
softer  than  expectation.  Revenue  declined  by  2.6%  QoQ  to  Rs4,349.9m  (PLe: 
Rs4,384m  Cons:  Rs4,385m)  and  flattish  in  USD  terms  to  US$72.66m  (PLe: 
US$73.4m, Cons: US$73.4m). EBITDA margins eroded by 519bps to 21.8% (PLe: 
24%, Cons: 24%) due to higher S&M cost (investment and wage hike ~7%), and 
currency  appreciation.  EPS  grew  by  2.4%  QoQ  to  Rs17.2  (PLe:  Rs17.2,  Cons: 
Rs16.8) due to forex gain of Rs133m (Q4FY14 loss of Rs87mn).  
 IP  had  better  than  seasonal  quarter,  client  addition  strong:  IP  revenue  for 
Q1FY15 tracked better than seasonality expectation. The growth outlook for IP 
in  FY15  continues  to  be  strong.  The  investment  in  sales  and  marketing  has 
started  showing  early  traction  with  76  new  clients’  addition  in  Q1FY15.  The 
management continues to hold the view of stronger FY15 than FY14.  
 S&M  investment  and  wage  hike  –  Margin  headwinds:  The  management 
continues to invest in S&M team expanding their workforce by 52 QoQ (18 new 
additions and rest reclassification of account managers as S&M that was earlier 
classified in technical) to 202. We believe S&M investment, which will continue 
through FY15, is right strategic move as Persistent gears up for enterprise sales. 
Moreover,  the  wage  hike  for  technical  workforce  would  be  headwind  to  the 
margin in Q2FY15. However, non‐recurring visa cost, room for higher utilization, 
and seasonally strong IP‐revenue would give margin tailwind in FY15. 
 Valuation & Recommendation: Persistent has delivered the margin and revenue 
performance in FY14, but heightened consensus expectation leave limited scope 
for earnings upgrade. However, the constant pursuits to inorganic opportunity 
leave  room  for  surprises.  Despite,  high‐teen  revenue  performance,  margin 
headwinds  would yield decelerated  earnings  growth.  We Retain  ‘Accumulate’ 
with revised target price of Rs1,285 (Old: Rs1,130). 
 
   
Key financials (Y/e March)    2013 2014  2015E 2016E
Revenues (Rs m)  12,945 16,692  19,228 22,745
     Growth (%)  29.4 28.9  15.2 18.3
EBITDA (Rs m)  3,352 4,303  4,885 5,746
PAT (Rs m)  1,876 2,493  3,144 3,770
EPS (Rs)  46.9 62.3  78.6 94.2
     Growth (%)  32.3 32.9  26.1 19.9
Net DPS (Rs)  8.5 11.3  13.2 15.1
 
Profitability & Valuation    2013 2014  2015E 2016E
EBITDA margin (%)  25.9 25.8  25.4 25.3
RoE (%)  20.2 22.3  23.2 23.0
RoCE (%)  19.4 21.7  22.4 22.4
EV / sales (x)  4.0 3.0  2.6 2.2
EV / EBITDA (x)  15.4 11.8  10.3 8.6
PE (x)  27.4 20.6  16.3 13.6
P / BV (x)  5.0 4.2  3.5 2.9
Net dividend yield (%)  0.7 0.9  1.0 1.2
Source: Company Data; PL Research 
   
July 28, 2014  2
  Persistent Systems 
Exhibit 1: Revenue and margin lower than expected (Rs m) 
Y/e March  Q1FY15  Q4FY14  QoQ Q1FY14 YoY Cons  PLe Var (Act. Vs Est.)
Sales ($ m)   72.7   72.6  0.0%  63.0  15.3%  73.4   73.4  ‐1.0%
Period Average Rate   59.87   61.50  ‐2.7%  56.7  5.6%  59.7   59.7 
Sales   4,349.9   4,467  ‐2.6%  3,572.9  21.7%  4,385.0   4,383.7  ‐0.8%
  
EBITDA   949.0   1,206.5  ‐21.3%  776.9  22.1%  1,053.0   1,052.1  ‐9.8%
EBITDA Margin  21.8%  27.0%  ‐519 bps 21.7% 7 bps 24.0%  24.0% ‐218 bps
  
PBT    954.2   923.3  3.3%  803.1  18.8%  944.0   947.2  0.7%
Tax   266.1  251.3  5.9% 232.2 14.6%  268.3  255.7 4.1%
  Tax Rate  27.9%  27.2%  67 bps 28.9% ‐102 bps 28.4%  27.0% 89 bps
  
PAT   688.0   672.0  2.4%  571.0  20.5%  675.7   691.5  ‐0.5%
EPS (Rs)   17.2   16.7  2.9%  14.2  21.1%  16.8   17.2  0.0%
Source: Company Data, Bloomberg, PL Research 
Exhibit 2: S&M investment continues – Continues ramping‐up the sales team 
   Q1FY15 Q4FY14  QoQ  Q1FY14 YoY
Sales & Business Development  202   150  34.7%   119  69.7%
S&M Expense   389   342  13.9%   319  21.8%
S&M (% of Revs)  8.9% 7.6%  129 bps  8.9% 1 bps
Source: Company Data, PL Research 
Exhibit 3: Strong growth in America and Europe 
By Geography ($m)  Q1FY15 Q4FY14  QoQ  Q1FY14 YoY
America   62.4   62.0  0.6%   55.2  13.0%
Europe   4.7   4.4  6.6%   3.0  56.1%
RoW   5.5   6.2  ‐10.6%   4.8  15.3%
  
% of Total 
America  85.9% 85.4%  50 bps  87.6% ‐170 bps
Europe  6.5% 6.1%  40 bps  4.8% 170 bps
Row  7.6% 8.5%  ‐90 bps  7.6% 0 bps
Source: Company Data, PL Research 
   
July 28, 2014  3
  Persistent Systems 
Exhibit 4: Strong growth in Telecom  
By Vertical Offering ($ m)  Q1FY15 Q4FY14  QoQ  Q1FY14 YoY
Telecom   13.4   11.1  20.9%   13.0  3.0%
Infrastructure and BFSI   49.7   52.0  ‐4.4%   43.6  14.1%
Life Sciences & Healthcare   9.5   9.5  0.0%   6.4  48.1%
  
% of Total 
Telecom  18.5% 15.3%  320 bps  20.7% ‐220 bps
Infrastructure and Systems  68.4% 71.6%  ‐320 bps  69.1% ‐70 bps
Life Sciences & BFSI  13.1% 13.1%  0 bps  10.2% 290 bps
Source: Company Data, PL Research 
Exhibit 5: Pricing likely to remain stable at this level, Yield flattish 
Delivery Split  Q1FY15 Q4FY14  QoQ  Q1FY14 YoY
Onsite   16.8   15.5  8.0%   13.4  25.6%
Offshore   41.3   42.9  ‐3.5%   40.2  3.0%
IP Driven   14.5   14.2  2.1%   9.5  52.7%
  
Fee Revenue 
Onsite  23.1% 21.4%  170 bps  21.2% 190 bps
Offshore  56.9% 59.0%  ‐210 bps  63.7% ‐680 bps
IP Driven  20.0% 19.6%  40 bps  15.1% 490 bps
  
Pricing (USD/ person month)
Onsite   14,905   14,355  3.8%   14,567  2.3%
Offshore   4,219   4,241  ‐0.5%   4,111  2.6%
Yield  3915.0 3927.0  ‐0.3%  3602.0 8.7%
Source: Company Data, PL Research 
Exhibit 6: IP‐led revenue strong despite seasonality 
By Business Offering ($ m)  Q1FY15 Q4FY14  QoQ  Q1FY14 YoY
Product Engineering & Platform  58.1   58.4  ‐0.5%   53.5  8.6%
IP Led   14.5   14.2  2.1%   9.5  52.7%
  
% of Total 
Product Engineering & Platform 80.0% 80.4%  ‐40 bps  84.9% ‐490 bps
IP Led  20.0% 19.6%  40 bps  15.1% 490 bps
Source: Company Data, PL Research 
   
July 28, 2014  4
  Persistent Systems 
Exhibit 7: Attrition up in‐line with industry 
Manpower details  Q1FY15 Q4FY14  QoQ  Q1FY14 YoY
Billable   16,139   16,155  ‐0.1%   15,161  6.5%
Billed   10,925   11,183  ‐2.3%   10,607  3.0%
IP Led   2,419   2,343  3.2%   2,335  3.6%
Sales & Business Development  202  150  34.7%  119 69.7%
Support   403  358  12.6%  336 19.9%
Technical   7,271   7,349  ‐1.1%   6,689  8.7%
Total   7,876   7,857  0.2%   7,144  10.2%
DSO   69   63  9.5%   65  6.2%
Attrition (LTM)  14.0% 13.4%  60 bps  14.2% ‐20 bps
Source: Company Data, PL Research 
Exhibit 8: Weak growth from top 5 clients 
Client Details  Q1FY15 Q4FY14  QoQ  Q1FY14 YoY
Large > $ 3m   14   15  ‐6.7%   15  ‐6.7%
Medium > $ 1m, < $ 3m   38   36  5.6%   30  26.7%
Prod. Eng. & Platforms   260   261  ‐0.4%   253  2.8%
IP Led   347   358  ‐3.1%   387  ‐10.3%
  
Top Client   15.1   15.3  ‐1.4%   13.4  13.1%
Top 2‐5 Clients   13.0   13.3  ‐2.2%   9.6  35.8%
Top 5 Clients   28.1   28.6  ‐1.7%   22.9  22.6%
Top 6‐10 Clients   7.5   6.6  13.2%   6.9  8.9%
Top 10 Clients   35.6   35.2  1.1%   29.8  19.4%
Non Top 10 Clients   37.1   37.4  ‐0.9%   33.2  11.6%
  
% of Total 
Top Client  20.8% 21.1%  ‐30 bps  21.2% ‐40 bps
Top 5 Clients  38.7% 39.4%  ‐70 bps  36.4% 230 bps
Top 10 Clients  49.0% 48.5%  50 bps  47.3% 170 bps
Non Top 10 Clients  51.0% 51.5%  ‐50 bps  52.7% ‐170 bps
  
Revenue from repeat business  63.0   61.9  1.8%   52.3  20.4%
Non‐repeat business   9.7   10.8  ‐10.1%   10.7  ‐9.8%
  
% of Total 
New Business  13.3% 14.8%  ‐150 bps  17.0% ‐370 bps
Repeat Business  86.7% 85.2%  150 bps  83.0% 370 bps
Source: Company Data, PL Research 
 
   
   
July 28, 2014  5
  Persistent Systems 
Income Statement (Rs m)           
Y/e March   2013  2014  2015E 2016E
Net Revenue  12,945  16,692  19,228 22,745
Raw Material Expenses  —  —  — —
Gross Profit  12,945  16,692  19,228 22,745
Employee Cost  8,888  11,406  13,192 15,679
Other Expenses  705  983  1,151 1,319
EBITDA  3,352  4,303  4,885 5,746
Depr. & Amortization  783  1,026  1,007 1,180
Net Interest  —  78  (21) 1
Other Income  61  228  468 529
Profit before Tax  2,630  3,427  4,367 5,094
Total Tax  754  934  1,223 1,324
Profit after Tax  1,876  2,493  3,144 3,770
Ex‐Od items / Min. Int.  —  —  — —
Adj. PAT  1,876  2,493  3,144 3,770
Avg. Shares O/S (m)  40.0  40.0  40.0 40.0
EPS (Rs.)  46.9  62.3  78.6 94.2
 
Cash Flow Abstract (Rs m)    
Y/e March     2013  2014  2015E 2016E
C/F from Operations  2,163  2,808  3,592 4,242
C/F from Investing  (1,711)  (1,958)  (2,307) (2,729)
C/F from Financing  (386)  (516)  (404) (603)
Inc. / Dec. in Cash  66  334  881 910
Opening Cash  433  499  833 1,714
Closing Cash  499  833  1,714 2,624
FCFF  1,352  1,789  1,285 1,513
FCFE  1,928  1,561  1,285 1,513
 
 
 
Key Financial Metrics 
Y/e March             2013  2014  2015E 2016E
Growth     
Revenue (%)  29.4  28.9  15.2 18.3
EBITDA (%)  44.2  28.4  13.5 17.6
PAT (%)  32.3  32.9  26.1 19.9
EPS (%)  32.3  32.9  26.1 19.9
Profitability     
EBITDA Margin (%)  25.9  25.8  25.4 25.3
PAT Margin (%)  14.5  14.9  16.4 16.6
RoCE (%)  19.4  21.7  22.4 22.4
RoE (%)  20.2  22.3  23.2 23.0
Balance Sheet     
Net Debt : Equity  —  —  (0.1) (0.1)
Net Wrkng Cap. (days)  —  —  — —
Valuation     
PER (x)  27.4  20.6  16.3 13.6
P / B (x)  5.0  4.2  3.5 2.9
EV / EBITDA (x)  15.4  11.8  10.3 8.6
EV / Sales (x)  4.0  3.0  2.6 2.2
Earnings Quality     
Eff. Tax Rate  28.7  27.3  28.0 26.0
Other Inc / PBT  2.3  6.7  10.7 10.4
Eff. Depr. Rate (%)  11.3  12.0  9.3 8.7
FCFE / PAT  102.8  62.6  40.9 40.1
Source: Company Data, PL Research. 
 
   
Balance Sheet Abstract (Rs m)   
Y/e March      2013  2014  2015E 2016E
Shareholder's Funds  10,183  12,223  14,840 18,006
Total Debt  653  426  426 426
Other Liabilities  —  —  — —
Total Liabilities  10,836  12,649  15,266 18,432
Net Fixed Assets  4,677  4,362  5,662 7,212
Goodwill  721  620  620 620
Investments  3,289  4,895  4,895 4,895
Net Current Assets  1,959  2,512  3,829 5,445
     Cash & Equivalents  561  957  1,714 2,624
     Other Current Assets  3,291  4,340  5,151 6,392
     Current Liabilities  1,894  2,785  3,037 3,570
Other Assets  190  260  260 260
Total Assets  10,836  12,649  15,266 18,432
 
 
 
 
Quarterly Financials (Rs m)     
Y/e March      Q2FY14  Q3FY14  Q4FY14 Q1FY15
Net Revenue  4,324  4,328  4,467 4,350
EBITDA  1,122  1,197  1,207 949
% of revenue  26.0  27.7  27.0 21.8
Depr. & Amortization  263  262  264 228
Net Interest  (75)  147  87 (133)
Other Income  (100)  77  68 100
Profit before Tax  835  865  923 954
Total Tax  227  223  251 266
Profit after Tax  608  642  672 688
Adj. PAT  608  642  672 688
 
Key Operating Metrics 
Y/e March       2013  2014 2015E 2016E
Volume (persons month)  41,176  44,033 50,638 59,246
Realization (US$ / person month)  3,686  3,847 3,905 3,998
Currency (USDINR)  54.5  60.9 59.8 59.0
SW Devp. Cost (% of sales)  68.7  68.3 68.6 68.9
SG&A (% of sales)  5.4  5.9 6.0 5.8
Revenue (US$ m)  237.8  275.7 321.8 385.5
EBITDA Margin Expansion/(Erosion) (bps)  0.7  (1.4) 75.0 (200.0)
Tax Rate (%)  28.7  27.3 28.0 26.0
Source: Company Data, PL Research. 
 
   
July 28, 2014  6
  Persistent Systems 
 
 
 
 
 
Prabhudas Lilladher Pvt. Ltd. 
3rd Floor, Sadhana House, 570, P. B. Marg, Worli, Mumbai‐400 018, India 
Tel: (91 22) 6632 2222 Fax: (91 22) 6632 2209 
Rating Distribution of Research Coverage   
29.6%
50.9%
19.4%
0.0%
0%
10%
20%
30%
40%
50%
60%
BUY Accumulate Reduce Sell
% of Total Coverage
 
PL’s Recommendation Nomenclature     
BUY   :  Over 15% Outperformance to Sensex over 12‐months  Accumulate  :  Outperformance to Sensex over 12‐months 
Reduce  :  Underperformance to Sensex over 12‐months  Sell  :  Over 15% underperformance to Sensex over 12‐months 
Trading Buy  :  Over 10% absolute upside in 1‐month  Trading Sell  :  Over 10% absolute decline in 1‐month 
Not Rated (NR)  :  No specific call on the stock  Under Review (UR)  :  Rating likely to change shortly 
This  document  has  been  prepared  by  the  Research  Division  of  Prabhudas  Lilladher  Pvt.  Ltd.  Mumbai,  India  (PL)  and  is  meant  for  use  by  the  recipient  only  as 
information and is not for circulation.  This document is not to be reported or copied or made available to others without prior permission of PL. It should not be 
considered or taken as an offer to sell or a solicitation to buy or sell any security. 
The information contained in this report has been obtained from sources that are considered to be reliable. However, PL has not independently verified the accuracy 
or completeness of the same. Neither PL nor any of its affiliates, its directors or its employees accept any responsibility of whatsoever nature for the information, 
statements and opinion given, made available or expressed herein or for any omission therein. 
Recipients of this report should be aware that past performance is not necessarily a guide to future performance and value of investments can go down as well. The 
suitability  or  otherwise  of  any  investments  will  depend  upon  the  recipient's  particular  circumstances  and,  in  case  of  doubt,  advice  should  be  sought  from  an 
independent expert/advisor. 
Either PL or its affiliates or its directors or its employees or its representatives or its clients or their relatives may have position(s), make market, act as principal or 
engage in transactions of securities of companies referred to in this report and they may have used the research material prior to publication. 
We may from time to time solicit or perform investment banking or other services for any company mentioned in this document. 

Contenu connexe

Tendances

The regulatory response jeff balchin
The regulatory response   jeff balchinThe regulatory response   jeff balchin
The regulatory response jeff balchinScott Donald
 
Ratio analysis on Pharmaceutical Companies: A study of Bangladesh
Ratio analysis on Pharmaceutical Companies: A study of BangladeshRatio analysis on Pharmaceutical Companies: A study of Bangladesh
Ratio analysis on Pharmaceutical Companies: A study of BangladeshAL Babur Rahman
 
Jeff balchin (pwc) presentation
Jeff balchin (pwc) presentationJeff balchin (pwc) presentation
Jeff balchin (pwc) presentationScott Donald
 
JBusch - Yield Leaders
JBusch - Yield LeadersJBusch - Yield Leaders
JBusch - Yield LeadersJim Busch
 
Stock Tip: Buy this stock for a target of Rs270
Stock Tip: Buy this stock for a target of Rs270Stock Tip: Buy this stock for a target of Rs270
Stock Tip: Buy this stock for a target of Rs270IndiaNotes.com
 
EPIC RESEARCH SINGAPORE - Daily SGX Singapore report of 20 April 2015
EPIC RESEARCH SINGAPORE - Daily SGX Singapore report of 20 April 2015EPIC RESEARCH SINGAPORE - Daily SGX Singapore report of 20 April 2015
EPIC RESEARCH SINGAPORE - Daily SGX Singapore report of 20 April 2015Epic Research Singapore
 
Idea Cellular Ltd. Q2 FY16 Result First Cut
Idea Cellular Ltd. Q2 FY16 Result First Cut Idea Cellular Ltd. Q2 FY16 Result First Cut
Idea Cellular Ltd. Q2 FY16 Result First Cut choice broking
 
Presentation fin 401 slide
Presentation fin 401 slide Presentation fin 401 slide
Presentation fin 401 slide Manjerul Islam
 
AmCham Taipei 2016 Business Climate Survey - Full results Jan 19
AmCham Taipei 2016 Business Climate Survey - Full results Jan 19AmCham Taipei 2016 Business Climate Survey - Full results Jan 19
AmCham Taipei 2016 Business Climate Survey - Full results Jan 19Gordon Stewart
 
Beazley - Interim Results 2014
Beazley - Interim Results 2014Beazley - Interim Results 2014
Beazley - Interim Results 2014Company Spotlight
 
15 jul 10.qbe business sentiment survey jul 2010 - data extract
15 jul 10.qbe business sentiment survey   jul 2010 - data extract15 jul 10.qbe business sentiment survey   jul 2010 - data extract
15 jul 10.qbe business sentiment survey jul 2010 - data extractQBE European Operations
 
Data extract jul-2010 qbe business sentiment survey
Data extract jul-2010 qbe business sentiment surveyData extract jul-2010 qbe business sentiment survey
Data extract jul-2010 qbe business sentiment surveyQBE European Operations
 
Investing When Valuations are High
Investing When Valuations are HighInvesting When Valuations are High
Investing When Valuations are HighQuantum Mutual Fund
 

Tendances (20)

gs retail 007070 Algorithm Investment Report
gs retail 007070 Algorithm Investment Reportgs retail 007070 Algorithm Investment Report
gs retail 007070 Algorithm Investment Report
 
The regulatory response jeff balchin
The regulatory response   jeff balchinThe regulatory response   jeff balchin
The regulatory response jeff balchin
 
Ratio analysis on Pharmaceutical Companies: A study of Bangladesh
Ratio analysis on Pharmaceutical Companies: A study of BangladeshRatio analysis on Pharmaceutical Companies: A study of Bangladesh
Ratio analysis on Pharmaceutical Companies: A study of Bangladesh
 
418 Homework 2
418 Homework 2418 Homework 2
418 Homework 2
 
Jeff balchin (pwc) presentation
Jeff balchin (pwc) presentationJeff balchin (pwc) presentation
Jeff balchin (pwc) presentation
 
JBusch - Yield Leaders
JBusch - Yield LeadersJBusch - Yield Leaders
JBusch - Yield Leaders
 
Stock Tip: Buy this stock for a target of Rs270
Stock Tip: Buy this stock for a target of Rs270Stock Tip: Buy this stock for a target of Rs270
Stock Tip: Buy this stock for a target of Rs270
 
EPIC RESEARCH SINGAPORE - Daily SGX Singapore report of 20 April 2015
EPIC RESEARCH SINGAPORE - Daily SGX Singapore report of 20 April 2015EPIC RESEARCH SINGAPORE - Daily SGX Singapore report of 20 April 2015
EPIC RESEARCH SINGAPORE - Daily SGX Singapore report of 20 April 2015
 
samsung sdi 006400 Algorithm Investment Report
samsung sdi 006400 Algorithm Investment Reportsamsung sdi 006400 Algorithm Investment Report
samsung sdi 006400 Algorithm Investment Report
 
daewoong pharmaceutical 069620 Algorithm Investment Report
daewoong pharmaceutical 069620 Algorithm Investment Reportdaewoong pharmaceutical 069620 Algorithm Investment Report
daewoong pharmaceutical 069620 Algorithm Investment Report
 
Idea Cellular Ltd. Q2 FY16 Result First Cut
Idea Cellular Ltd. Q2 FY16 Result First Cut Idea Cellular Ltd. Q2 FY16 Result First Cut
Idea Cellular Ltd. Q2 FY16 Result First Cut
 
Presentation fin 401 slide
Presentation fin 401 slide Presentation fin 401 slide
Presentation fin 401 slide
 
AmCham Taipei 2016 Business Climate Survey - Full results Jan 19
AmCham Taipei 2016 Business Climate Survey - Full results Jan 19AmCham Taipei 2016 Business Climate Survey - Full results Jan 19
AmCham Taipei 2016 Business Climate Survey - Full results Jan 19
 
sajo dongaone 008040 Algorithm Investment Report
sajo dongaone 008040 Algorithm Investment Reportsajo dongaone 008040 Algorithm Investment Report
sajo dongaone 008040 Algorithm Investment Report
 
Beazley - Interim Results 2014
Beazley - Interim Results 2014Beazley - Interim Results 2014
Beazley - Interim Results 2014
 
Beazley
BeazleyBeazley
Beazley
 
15 jul 10.qbe business sentiment survey jul 2010 - data extract
15 jul 10.qbe business sentiment survey   jul 2010 - data extract15 jul 10.qbe business sentiment survey   jul 2010 - data extract
15 jul 10.qbe business sentiment survey jul 2010 - data extract
 
Data extract jul-2010 qbe business sentiment survey
Data extract jul-2010 qbe business sentiment surveyData extract jul-2010 qbe business sentiment survey
Data extract jul-2010 qbe business sentiment survey
 
Investing When Valuations are High
Investing When Valuations are HighInvesting When Valuations are High
Investing When Valuations are High
 
Chase Corp
Chase CorpChase Corp
Chase Corp
 

Similaire à Persistent Systems Q1FY15: Soft performance, margin headwinds limit near term upside

Hexaware Technologies Q1FY15: Margin troughed, sales uptick likely; accumulat...
Hexaware Technologies Q1FY15: Margin troughed, sales uptick likely; accumulat...Hexaware Technologies Q1FY15: Margin troughed, sales uptick likely; accumulat...
Hexaware Technologies Q1FY15: Margin troughed, sales uptick likely; accumulat...IndiaNotes.com
 
KSB Pumps Q3CY14 Result Update: Weak margin performance - Prabhudas Lilladher
KSB Pumps Q3CY14 Result Update: Weak margin performance - Prabhudas LilladherKSB Pumps Q3CY14 Result Update: Weak margin performance - Prabhudas Lilladher
KSB Pumps Q3CY14 Result Update: Weak margin performance - Prabhudas LilladherIndiaNotes.com
 
Nirmal pi industries_03_aug15
Nirmal pi industries_03_aug15Nirmal pi industries_03_aug15
Nirmal pi industries_03_aug15IndiaNotes.com
 
Alembic Pharma Q1FY15: EBITDA margins improved by ~285 bps y-o-y; Hold
 Alembic Pharma Q1FY15: EBITDA margins improved by ~285 bps y-o-y; Hold Alembic Pharma Q1FY15: EBITDA margins improved by ~285 bps y-o-y; Hold
Alembic Pharma Q1FY15: EBITDA margins improved by ~285 bps y-o-y; HoldIndiaNotes.com
 
Dr. Reddy's 1FY15: Strong sales in key markets drive growth, margins
 Dr. Reddy's 1FY15: Strong sales in key markets drive growth, margins Dr. Reddy's 1FY15: Strong sales in key markets drive growth, margins
Dr. Reddy's 1FY15: Strong sales in key markets drive growth, marginsIndiaNotes.com
 
Zensar Technologies Q1FY15: Results in line with our expectations, buy
 Zensar Technologies Q1FY15: Results in line with our expectations, buy Zensar Technologies Q1FY15: Results in line with our expectations, buy
Zensar Technologies Q1FY15: Results in line with our expectations, buyIndiaNotes.com
 
Q2FY15: Hold Mahindra &amp; Mahindra Financial Services - Nirmal Bang
Q2FY15: Hold Mahindra &amp; Mahindra Financial Services - Nirmal BangQ2FY15: Hold Mahindra &amp; Mahindra Financial Services - Nirmal Bang
Q2FY15: Hold Mahindra &amp; Mahindra Financial Services - Nirmal BangIndiaNotes.com
 
Prabhudas lilladher techmahindra_29june_2015
Prabhudas lilladher techmahindra_29june_2015Prabhudas lilladher techmahindra_29june_2015
Prabhudas lilladher techmahindra_29june_2015IndiaNotes.com
 
Cipla Q2 disappoints, gearing up for strong H2FY15E
Cipla Q2 disappoints, gearing up for strong H2FY15ECipla Q2 disappoints, gearing up for strong H2FY15E
Cipla Q2 disappoints, gearing up for strong H2FY15EIndiaNotes.com
 
PI Industries: Another strong performance; Sales up 16% in Q1FY15
 PI Industries: Another strong performance; Sales up 16% in Q1FY15 PI Industries: Another strong performance; Sales up 16% in Q1FY15
PI Industries: Another strong performance; Sales up 16% in Q1FY15IndiaNotes.com
 
J&K Bank: Asset quality risks concerns persist; Profit de-grew 60% in Q4
J&K Bank: Asset quality risks concerns persist; Profit de-grew 60% in Q4J&K Bank: Asset quality risks concerns persist; Profit de-grew 60% in Q4
J&K Bank: Asset quality risks concerns persist; Profit de-grew 60% in Q4IndiaNotes.com
 
Punjab National Bank Q1FY15: Sane performance sanity in the quarter
 Punjab National Bank Q1FY15: Sane performance sanity in the quarter Punjab National Bank Q1FY15: Sane performance sanity in the quarter
Punjab National Bank Q1FY15: Sane performance sanity in the quarterIndiaNotes.com
 
HGSL 1QFY18
HGSL 1QFY18HGSL 1QFY18
HGSL 1QFY18Mohit Jn
 
Sun Pharma: Compelling valuation post stake sale of Daiichi; Buy
Sun Pharma: Compelling valuation post stake sale of Daiichi; BuySun Pharma: Compelling valuation post stake sale of Daiichi; Buy
Sun Pharma: Compelling valuation post stake sale of Daiichi; BuyIndiaNotes.com
 
LIC Housing Finance Q1FY15 performance in line with estimates; buy
 LIC Housing Finance Q1FY15 performance in line with estimates; buy LIC Housing Finance Q1FY15 performance in line with estimates; buy
LIC Housing Finance Q1FY15 performance in line with estimates; buyIndiaNotes.com
 
Bajaj Finance Q1FY15: AUM growth remained strong at Rs269.4 bn, buy
Bajaj Finance Q1FY15: AUM growth remained strong at Rs269.4 bn, buyBajaj Finance Q1FY15: AUM growth remained strong at Rs269.4 bn, buy
Bajaj Finance Q1FY15: AUM growth remained strong at Rs269.4 bn, buyIndiaNotes.com
 
Zee 1QFY18
Zee 1QFY18Zee 1QFY18
Zee 1QFY18Mohit Jn
 
Mahindra Financial result update: 4QFY15 PAT up 7% YoY and 144% QoQ
Mahindra Financial result update: 4QFY15 PAT up 7% YoY and 144% QoQMahindra Financial result update: 4QFY15 PAT up 7% YoY and 144% QoQ
Mahindra Financial result update: 4QFY15 PAT up 7% YoY and 144% QoQIndiaNotes.com
 
Zydus Wellness reports a subdued quarter, hold - Nirmal Bang
Zydus Wellness reports a subdued quarter, hold - Nirmal BangZydus Wellness reports a subdued quarter, hold - Nirmal Bang
Zydus Wellness reports a subdued quarter, hold - Nirmal BangIndiaNotes.com
 
Pl shree cement_04may15[1]
Pl shree cement_04may15[1]Pl shree cement_04may15[1]
Pl shree cement_04may15[1]IndiaNotes.com
 

Similaire à Persistent Systems Q1FY15: Soft performance, margin headwinds limit near term upside (20)

Hexaware Technologies Q1FY15: Margin troughed, sales uptick likely; accumulat...
Hexaware Technologies Q1FY15: Margin troughed, sales uptick likely; accumulat...Hexaware Technologies Q1FY15: Margin troughed, sales uptick likely; accumulat...
Hexaware Technologies Q1FY15: Margin troughed, sales uptick likely; accumulat...
 
KSB Pumps Q3CY14 Result Update: Weak margin performance - Prabhudas Lilladher
KSB Pumps Q3CY14 Result Update: Weak margin performance - Prabhudas LilladherKSB Pumps Q3CY14 Result Update: Weak margin performance - Prabhudas Lilladher
KSB Pumps Q3CY14 Result Update: Weak margin performance - Prabhudas Lilladher
 
Nirmal pi industries_03_aug15
Nirmal pi industries_03_aug15Nirmal pi industries_03_aug15
Nirmal pi industries_03_aug15
 
Alembic Pharma Q1FY15: EBITDA margins improved by ~285 bps y-o-y; Hold
 Alembic Pharma Q1FY15: EBITDA margins improved by ~285 bps y-o-y; Hold Alembic Pharma Q1FY15: EBITDA margins improved by ~285 bps y-o-y; Hold
Alembic Pharma Q1FY15: EBITDA margins improved by ~285 bps y-o-y; Hold
 
Dr. Reddy's 1FY15: Strong sales in key markets drive growth, margins
 Dr. Reddy's 1FY15: Strong sales in key markets drive growth, margins Dr. Reddy's 1FY15: Strong sales in key markets drive growth, margins
Dr. Reddy's 1FY15: Strong sales in key markets drive growth, margins
 
Zensar Technologies Q1FY15: Results in line with our expectations, buy
 Zensar Technologies Q1FY15: Results in line with our expectations, buy Zensar Technologies Q1FY15: Results in line with our expectations, buy
Zensar Technologies Q1FY15: Results in line with our expectations, buy
 
Q2FY15: Hold Mahindra &amp; Mahindra Financial Services - Nirmal Bang
Q2FY15: Hold Mahindra &amp; Mahindra Financial Services - Nirmal BangQ2FY15: Hold Mahindra &amp; Mahindra Financial Services - Nirmal Bang
Q2FY15: Hold Mahindra &amp; Mahindra Financial Services - Nirmal Bang
 
Prabhudas lilladher techmahindra_29june_2015
Prabhudas lilladher techmahindra_29june_2015Prabhudas lilladher techmahindra_29june_2015
Prabhudas lilladher techmahindra_29june_2015
 
Cipla Q2 disappoints, gearing up for strong H2FY15E
Cipla Q2 disappoints, gearing up for strong H2FY15ECipla Q2 disappoints, gearing up for strong H2FY15E
Cipla Q2 disappoints, gearing up for strong H2FY15E
 
PI Industries: Another strong performance; Sales up 16% in Q1FY15
 PI Industries: Another strong performance; Sales up 16% in Q1FY15 PI Industries: Another strong performance; Sales up 16% in Q1FY15
PI Industries: Another strong performance; Sales up 16% in Q1FY15
 
J&K Bank: Asset quality risks concerns persist; Profit de-grew 60% in Q4
J&K Bank: Asset quality risks concerns persist; Profit de-grew 60% in Q4J&K Bank: Asset quality risks concerns persist; Profit de-grew 60% in Q4
J&K Bank: Asset quality risks concerns persist; Profit de-grew 60% in Q4
 
Punjab National Bank Q1FY15: Sane performance sanity in the quarter
 Punjab National Bank Q1FY15: Sane performance sanity in the quarter Punjab National Bank Q1FY15: Sane performance sanity in the quarter
Punjab National Bank Q1FY15: Sane performance sanity in the quarter
 
HGSL 1QFY18
HGSL 1QFY18HGSL 1QFY18
HGSL 1QFY18
 
Sun Pharma: Compelling valuation post stake sale of Daiichi; Buy
Sun Pharma: Compelling valuation post stake sale of Daiichi; BuySun Pharma: Compelling valuation post stake sale of Daiichi; Buy
Sun Pharma: Compelling valuation post stake sale of Daiichi; Buy
 
LIC Housing Finance Q1FY15 performance in line with estimates; buy
 LIC Housing Finance Q1FY15 performance in line with estimates; buy LIC Housing Finance Q1FY15 performance in line with estimates; buy
LIC Housing Finance Q1FY15 performance in line with estimates; buy
 
Bajaj Finance Q1FY15: AUM growth remained strong at Rs269.4 bn, buy
Bajaj Finance Q1FY15: AUM growth remained strong at Rs269.4 bn, buyBajaj Finance Q1FY15: AUM growth remained strong at Rs269.4 bn, buy
Bajaj Finance Q1FY15: AUM growth remained strong at Rs269.4 bn, buy
 
Zee 1QFY18
Zee 1QFY18Zee 1QFY18
Zee 1QFY18
 
Mahindra Financial result update: 4QFY15 PAT up 7% YoY and 144% QoQ
Mahindra Financial result update: 4QFY15 PAT up 7% YoY and 144% QoQMahindra Financial result update: 4QFY15 PAT up 7% YoY and 144% QoQ
Mahindra Financial result update: 4QFY15 PAT up 7% YoY and 144% QoQ
 
Zydus Wellness reports a subdued quarter, hold - Nirmal Bang
Zydus Wellness reports a subdued quarter, hold - Nirmal BangZydus Wellness reports a subdued quarter, hold - Nirmal Bang
Zydus Wellness reports a subdued quarter, hold - Nirmal Bang
 
Pl shree cement_04may15[1]
Pl shree cement_04may15[1]Pl shree cement_04may15[1]
Pl shree cement_04may15[1]
 

Plus de IndiaNotes.com

Fce glaxo smithkline_12aug15
Fce glaxo smithkline_12aug15Fce glaxo smithkline_12aug15
Fce glaxo smithkline_12aug15IndiaNotes.com
 
GSK Consumer: Horlicks strengthens its position as No.1 brand across India
GSK Consumer: Horlicks strengthens its position as No.1 brand across IndiaGSK Consumer: Horlicks strengthens its position as No.1 brand across India
GSK Consumer: Horlicks strengthens its position as No.1 brand across IndiaIndiaNotes.com
 
GSK Consumer: Horlicks strengthens its position as No.1 brand across India
GSK Consumer: Horlicks strengthens its position as No.1 brand across IndiaGSK Consumer: Horlicks strengthens its position as No.1 brand across India
GSK Consumer: Horlicks strengthens its position as No.1 brand across IndiaIndiaNotes.com
 
Hester Biosciences gets manufacturing licence for 2 additional poultry vaccines
Hester Biosciences gets manufacturing licence for 2 additional poultry vaccinesHester Biosciences gets manufacturing licence for 2 additional poultry vaccines
Hester Biosciences gets manufacturing licence for 2 additional poultry vaccinesIndiaNotes.com
 
Vidhi Dyestuffs: To keep its growth story in the coming quarters also
Vidhi Dyestuffs: To keep its growth story in the coming quarters alsoVidhi Dyestuffs: To keep its growth story in the coming quarters also
Vidhi Dyestuffs: To keep its growth story in the coming quarters alsoIndiaNotes.com
 
Apollo Tyres approves further expansion of the Truck & Bus radial tyre capacity
Apollo Tyres approves further expansion of the Truck & Bus radial tyre capacityApollo Tyres approves further expansion of the Truck & Bus radial tyre capacity
Apollo Tyres approves further expansion of the Truck & Bus radial tyre capacityIndiaNotes.com
 
Grasim Industries reports improved performance in Q1FY16
Grasim Industries reports improved performance in Q1FY16Grasim Industries reports improved performance in Q1FY16
Grasim Industries reports improved performance in Q1FY16IndiaNotes.com
 
Cummins India: No interest burden being free from long-term or short-term debt
Cummins India: No interest burden being free from long-term or short-term debtCummins India: No interest burden being free from long-term or short-term debt
Cummins India: No interest burden being free from long-term or short-term debtIndiaNotes.com
 
Buy Makers Laboratories, company growing rapidly with strong thrust on brande...
Buy Makers Laboratories, company growing rapidly with strong thrust on brande...Buy Makers Laboratories, company growing rapidly with strong thrust on brande...
Buy Makers Laboratories, company growing rapidly with strong thrust on brande...IndiaNotes.com
 
Buy Multibase India, globalisation of the auto component sector to benefit th...
Buy Multibase India, globalisation of the auto component sector to benefit th...Buy Multibase India, globalisation of the auto component sector to benefit th...
Buy Multibase India, globalisation of the auto component sector to benefit th...IndiaNotes.com
 
Capital First: Long-term credit rating is rated highly at AA+ by CARE
Capital First: Long-term credit rating is rated highly at AA+ by CARECapital First: Long-term credit rating is rated highly at AA+ by CARE
Capital First: Long-term credit rating is rated highly at AA+ by CAREIndiaNotes.com
 
Orient Cement: Best placed to benefit from demand revival in AP & Telengana r...
Orient Cement: Best placed to benefit from demand revival in AP & Telengana r...Orient Cement: Best placed to benefit from demand revival in AP & Telengana r...
Orient Cement: Best placed to benefit from demand revival in AP & Telengana r...IndiaNotes.com
 
Canara Bank's operating performance to improve in remaining 9MFY16E
Canara Bank's operating performance to improve in remaining 9MFY16ECanara Bank's operating performance to improve in remaining 9MFY16E
Canara Bank's operating performance to improve in remaining 9MFY16EIndiaNotes.com
 
Buy Jenburkt Pharmaceuticals; government's amended FDI policy to cover medica...
Buy Jenburkt Pharmaceuticals; government's amended FDI policy to cover medica...Buy Jenburkt Pharmaceuticals; government's amended FDI policy to cover medica...
Buy Jenburkt Pharmaceuticals; government's amended FDI policy to cover medica...IndiaNotes.com
 
Hexaware Technologies adds 9 clients in Q2CY15, Buy
Hexaware Technologies adds 9 clients in Q2CY15, BuyHexaware Technologies adds 9 clients in Q2CY15, Buy
Hexaware Technologies adds 9 clients in Q2CY15, BuyIndiaNotes.com
 
Indoco Remedies: Weak domestic growth offsets export revenues in Q1FY16; Hold
Indoco Remedies: Weak domestic growth offsets export revenues in Q1FY16; HoldIndoco Remedies: Weak domestic growth offsets export revenues in Q1FY16; Hold
Indoco Remedies: Weak domestic growth offsets export revenues in Q1FY16; HoldIndiaNotes.com
 
PI Industries: Custom synthesis exports deliver growth of ~26% in Q1FY16; Buy
PI Industries: Custom synthesis exports deliver growth of ~26% in Q1FY16; BuyPI Industries: Custom synthesis exports deliver growth of ~26% in Q1FY16; Buy
PI Industries: Custom synthesis exports deliver growth of ~26% in Q1FY16; BuyIndiaNotes.com
 
Torrent Pharma Q1FY16: IndiaNivesh maintain 'buy' for an upgraded price target
Torrent Pharma Q1FY16: IndiaNivesh maintain 'buy' for an upgraded price targetTorrent Pharma Q1FY16: IndiaNivesh maintain 'buy' for an upgraded price target
Torrent Pharma Q1FY16: IndiaNivesh maintain 'buy' for an upgraded price targetIndiaNotes.com
 

Plus de IndiaNotes.com (20)

Fce glaxo smithkline_12aug15
Fce glaxo smithkline_12aug15Fce glaxo smithkline_12aug15
Fce glaxo smithkline_12aug15
 
GSK Consumer: Horlicks strengthens its position as No.1 brand across India
GSK Consumer: Horlicks strengthens its position as No.1 brand across IndiaGSK Consumer: Horlicks strengthens its position as No.1 brand across India
GSK Consumer: Horlicks strengthens its position as No.1 brand across India
 
GSK Consumer: Horlicks strengthens its position as No.1 brand across India
GSK Consumer: Horlicks strengthens its position as No.1 brand across IndiaGSK Consumer: Horlicks strengthens its position as No.1 brand across India
GSK Consumer: Horlicks strengthens its position as No.1 brand across India
 
Hester Biosciences gets manufacturing licence for 2 additional poultry vaccines
Hester Biosciences gets manufacturing licence for 2 additional poultry vaccinesHester Biosciences gets manufacturing licence for 2 additional poultry vaccines
Hester Biosciences gets manufacturing licence for 2 additional poultry vaccines
 
Vidhi Dyestuffs: To keep its growth story in the coming quarters also
Vidhi Dyestuffs: To keep its growth story in the coming quarters alsoVidhi Dyestuffs: To keep its growth story in the coming quarters also
Vidhi Dyestuffs: To keep its growth story in the coming quarters also
 
Apollo Tyres approves further expansion of the Truck & Bus radial tyre capacity
Apollo Tyres approves further expansion of the Truck & Bus radial tyre capacityApollo Tyres approves further expansion of the Truck & Bus radial tyre capacity
Apollo Tyres approves further expansion of the Truck & Bus radial tyre capacity
 
Grasim Industries reports improved performance in Q1FY16
Grasim Industries reports improved performance in Q1FY16Grasim Industries reports improved performance in Q1FY16
Grasim Industries reports improved performance in Q1FY16
 
Cummins India: No interest burden being free from long-term or short-term debt
Cummins India: No interest burden being free from long-term or short-term debtCummins India: No interest burden being free from long-term or short-term debt
Cummins India: No interest burden being free from long-term or short-term debt
 
Buy Makers Laboratories, company growing rapidly with strong thrust on brande...
Buy Makers Laboratories, company growing rapidly with strong thrust on brande...Buy Makers Laboratories, company growing rapidly with strong thrust on brande...
Buy Makers Laboratories, company growing rapidly with strong thrust on brande...
 
Buy Multibase India, globalisation of the auto component sector to benefit th...
Buy Multibase India, globalisation of the auto component sector to benefit th...Buy Multibase India, globalisation of the auto component sector to benefit th...
Buy Multibase India, globalisation of the auto component sector to benefit th...
 
Capital First: Long-term credit rating is rated highly at AA+ by CARE
Capital First: Long-term credit rating is rated highly at AA+ by CARECapital First: Long-term credit rating is rated highly at AA+ by CARE
Capital First: Long-term credit rating is rated highly at AA+ by CARE
 
Orient Cement: Best placed to benefit from demand revival in AP & Telengana r...
Orient Cement: Best placed to benefit from demand revival in AP & Telengana r...Orient Cement: Best placed to benefit from demand revival in AP & Telengana r...
Orient Cement: Best placed to benefit from demand revival in AP & Telengana r...
 
Canara Bank's operating performance to improve in remaining 9MFY16E
Canara Bank's operating performance to improve in remaining 9MFY16ECanara Bank's operating performance to improve in remaining 9MFY16E
Canara Bank's operating performance to improve in remaining 9MFY16E
 
Nirmal lupin 06_aug15
Nirmal lupin 06_aug15Nirmal lupin 06_aug15
Nirmal lupin 06_aug15
 
Buy Jenburkt Pharmaceuticals; government's amended FDI policy to cover medica...
Buy Jenburkt Pharmaceuticals; government's amended FDI policy to cover medica...Buy Jenburkt Pharmaceuticals; government's amended FDI policy to cover medica...
Buy Jenburkt Pharmaceuticals; government's amended FDI policy to cover medica...
 
Hexaware Technologies adds 9 clients in Q2CY15, Buy
Hexaware Technologies adds 9 clients in Q2CY15, BuyHexaware Technologies adds 9 clients in Q2CY15, Buy
Hexaware Technologies adds 9 clients in Q2CY15, Buy
 
Indoco Remedies: Weak domestic growth offsets export revenues in Q1FY16; Hold
Indoco Remedies: Weak domestic growth offsets export revenues in Q1FY16; HoldIndoco Remedies: Weak domestic growth offsets export revenues in Q1FY16; Hold
Indoco Remedies: Weak domestic growth offsets export revenues in Q1FY16; Hold
 
Fce thermax 31_jul15
Fce thermax 31_jul15Fce thermax 31_jul15
Fce thermax 31_jul15
 
PI Industries: Custom synthesis exports deliver growth of ~26% in Q1FY16; Buy
PI Industries: Custom synthesis exports deliver growth of ~26% in Q1FY16; BuyPI Industries: Custom synthesis exports deliver growth of ~26% in Q1FY16; Buy
PI Industries: Custom synthesis exports deliver growth of ~26% in Q1FY16; Buy
 
Torrent Pharma Q1FY16: IndiaNivesh maintain 'buy' for an upgraded price target
Torrent Pharma Q1FY16: IndiaNivesh maintain 'buy' for an upgraded price targetTorrent Pharma Q1FY16: IndiaNivesh maintain 'buy' for an upgraded price target
Torrent Pharma Q1FY16: IndiaNivesh maintain 'buy' for an upgraded price target
 

Dernier

Diva-Thane European Call Girls Number-9833754194-Diva Busty Professional Call...
Diva-Thane European Call Girls Number-9833754194-Diva Busty Professional Call...Diva-Thane European Call Girls Number-9833754194-Diva Busty Professional Call...
Diva-Thane European Call Girls Number-9833754194-Diva Busty Professional Call...priyasharma62062
 
( Jasmin ) Top VIP Escorts Service Dindigul 💧 7737669865 💧 by Dindigul Call G...
( Jasmin ) Top VIP Escorts Service Dindigul 💧 7737669865 💧 by Dindigul Call G...( Jasmin ) Top VIP Escorts Service Dindigul 💧 7737669865 💧 by Dindigul Call G...
( Jasmin ) Top VIP Escorts Service Dindigul 💧 7737669865 💧 by Dindigul Call G...dipikadinghjn ( Why You Choose Us? ) Escorts
 
Mira Road Awesome 100% Independent Call Girls NUmber-9833754194-Dahisar Inter...
Mira Road Awesome 100% Independent Call Girls NUmber-9833754194-Dahisar Inter...Mira Road Awesome 100% Independent Call Girls NUmber-9833754194-Dahisar Inter...
Mira Road Awesome 100% Independent Call Girls NUmber-9833754194-Dahisar Inter...priyasharma62062
 
VIP Independent Call Girls in Andheri 🌹 9920725232 ( Call Me ) Mumbai Escorts...
VIP Independent Call Girls in Andheri 🌹 9920725232 ( Call Me ) Mumbai Escorts...VIP Independent Call Girls in Andheri 🌹 9920725232 ( Call Me ) Mumbai Escorts...
VIP Independent Call Girls in Andheri 🌹 9920725232 ( Call Me ) Mumbai Escorts...dipikadinghjn ( Why You Choose Us? ) Escorts
 
Best VIP Call Girls Morni Hills Just Click Me 6367492432
Best VIP Call Girls Morni Hills Just Click Me 6367492432Best VIP Call Girls Morni Hills Just Click Me 6367492432
Best VIP Call Girls Morni Hills Just Click Me 6367492432motiram463
 
Vasai-Virar Fantastic Call Girls-9833754194-Call Girls MUmbai
Vasai-Virar Fantastic Call Girls-9833754194-Call Girls MUmbaiVasai-Virar Fantastic Call Girls-9833754194-Call Girls MUmbai
Vasai-Virar Fantastic Call Girls-9833754194-Call Girls MUmbaipriyasharma62062
 
(Sexy Sheela) Call Girl Mumbai Call Now 👉9920725232👈 Mumbai Escorts 24x7
(Sexy Sheela) Call Girl Mumbai Call Now 👉9920725232👈 Mumbai Escorts 24x7(Sexy Sheela) Call Girl Mumbai Call Now 👉9920725232👈 Mumbai Escorts 24x7
(Sexy Sheela) Call Girl Mumbai Call Now 👉9920725232👈 Mumbai Escorts 24x7jayawati511
 
Cybersecurity Threats in Financial Services Protection.pptx
Cybersecurity Threats in  Financial Services Protection.pptxCybersecurity Threats in  Financial Services Protection.pptx
Cybersecurity Threats in Financial Services Protection.pptxLumiverse Solutions Pvt Ltd
 
VIP Independent Call Girls in Mira Bhayandar 🌹 9920725232 ( Call Me ) Mumbai ...
VIP Independent Call Girls in Mira Bhayandar 🌹 9920725232 ( Call Me ) Mumbai ...VIP Independent Call Girls in Mira Bhayandar 🌹 9920725232 ( Call Me ) Mumbai ...
VIP Independent Call Girls in Mira Bhayandar 🌹 9920725232 ( Call Me ) Mumbai ...dipikadinghjn ( Why You Choose Us? ) Escorts
 
➥🔝 7737669865 🔝▻ Malda Call-girls in Women Seeking Men 🔝Malda🔝 Escorts Ser...
➥🔝 7737669865 🔝▻ Malda Call-girls in Women Seeking Men  🔝Malda🔝   Escorts Ser...➥🔝 7737669865 🔝▻ Malda Call-girls in Women Seeking Men  🔝Malda🔝   Escorts Ser...
➥🔝 7737669865 🔝▻ Malda Call-girls in Women Seeking Men 🔝Malda🔝 Escorts Ser...amitlee9823
 
Pension dashboards forum 1 May 2024 (1).pdf
Pension dashboards forum 1 May 2024 (1).pdfPension dashboards forum 1 May 2024 (1).pdf
Pension dashboards forum 1 May 2024 (1).pdfHenry Tapper
 
Q1 2024 Conference Call Presentation vF.pdf
Q1 2024 Conference Call Presentation vF.pdfQ1 2024 Conference Call Presentation vF.pdf
Q1 2024 Conference Call Presentation vF.pdfAdnet Communications
 
Call Girls Banaswadi Just Call 👗 7737669865 👗 Top Class Call Girl Service Ban...
Call Girls Banaswadi Just Call 👗 7737669865 👗 Top Class Call Girl Service Ban...Call Girls Banaswadi Just Call 👗 7737669865 👗 Top Class Call Girl Service Ban...
Call Girls Banaswadi Just Call 👗 7737669865 👗 Top Class Call Girl Service Ban...amitlee9823
 
20240419-SMC-submission-Annual-Superannuation-Performance-Test-–-design-optio...
20240419-SMC-submission-Annual-Superannuation-Performance-Test-–-design-optio...20240419-SMC-submission-Annual-Superannuation-Performance-Test-–-design-optio...
20240419-SMC-submission-Annual-Superannuation-Performance-Test-–-design-optio...Henry Tapper
 
Strategic Resources May 2024 Corporate Presentation
Strategic Resources May 2024 Corporate PresentationStrategic Resources May 2024 Corporate Presentation
Strategic Resources May 2024 Corporate PresentationAdnet Communications
 
VIP Call Girl Service Andheri West ⚡ 9920725232 What It Takes To Be The Best ...
VIP Call Girl Service Andheri West ⚡ 9920725232 What It Takes To Be The Best ...VIP Call Girl Service Andheri West ⚡ 9920725232 What It Takes To Be The Best ...
VIP Call Girl Service Andheri West ⚡ 9920725232 What It Takes To Be The Best ...dipikadinghjn ( Why You Choose Us? ) Escorts
 
VIP Independent Call Girls in Bandra West 🌹 9920725232 ( Call Me ) Mumbai Esc...
VIP Independent Call Girls in Bandra West 🌹 9920725232 ( Call Me ) Mumbai Esc...VIP Independent Call Girls in Bandra West 🌹 9920725232 ( Call Me ) Mumbai Esc...
VIP Independent Call Girls in Bandra West 🌹 9920725232 ( Call Me ) Mumbai Esc...dipikadinghjn ( Why You Choose Us? ) Escorts
 
VIP Independent Call Girls in Taloja 🌹 9920725232 ( Call Me ) Mumbai Escorts ...
VIP Independent Call Girls in Taloja 🌹 9920725232 ( Call Me ) Mumbai Escorts ...VIP Independent Call Girls in Taloja 🌹 9920725232 ( Call Me ) Mumbai Escorts ...
VIP Independent Call Girls in Taloja 🌹 9920725232 ( Call Me ) Mumbai Escorts ...dipikadinghjn ( Why You Choose Us? ) Escorts
 
7 tips trading Deriv Accumulator Options
7 tips trading Deriv Accumulator Options7 tips trading Deriv Accumulator Options
7 tips trading Deriv Accumulator OptionsVince Stanzione
 

Dernier (20)

Diva-Thane European Call Girls Number-9833754194-Diva Busty Professional Call...
Diva-Thane European Call Girls Number-9833754194-Diva Busty Professional Call...Diva-Thane European Call Girls Number-9833754194-Diva Busty Professional Call...
Diva-Thane European Call Girls Number-9833754194-Diva Busty Professional Call...
 
( Jasmin ) Top VIP Escorts Service Dindigul 💧 7737669865 💧 by Dindigul Call G...
( Jasmin ) Top VIP Escorts Service Dindigul 💧 7737669865 💧 by Dindigul Call G...( Jasmin ) Top VIP Escorts Service Dindigul 💧 7737669865 💧 by Dindigul Call G...
( Jasmin ) Top VIP Escorts Service Dindigul 💧 7737669865 💧 by Dindigul Call G...
 
Mira Road Awesome 100% Independent Call Girls NUmber-9833754194-Dahisar Inter...
Mira Road Awesome 100% Independent Call Girls NUmber-9833754194-Dahisar Inter...Mira Road Awesome 100% Independent Call Girls NUmber-9833754194-Dahisar Inter...
Mira Road Awesome 100% Independent Call Girls NUmber-9833754194-Dahisar Inter...
 
VIP Independent Call Girls in Andheri 🌹 9920725232 ( Call Me ) Mumbai Escorts...
VIP Independent Call Girls in Andheri 🌹 9920725232 ( Call Me ) Mumbai Escorts...VIP Independent Call Girls in Andheri 🌹 9920725232 ( Call Me ) Mumbai Escorts...
VIP Independent Call Girls in Andheri 🌹 9920725232 ( Call Me ) Mumbai Escorts...
 
Best VIP Call Girls Morni Hills Just Click Me 6367492432
Best VIP Call Girls Morni Hills Just Click Me 6367492432Best VIP Call Girls Morni Hills Just Click Me 6367492432
Best VIP Call Girls Morni Hills Just Click Me 6367492432
 
Vasai-Virar Fantastic Call Girls-9833754194-Call Girls MUmbai
Vasai-Virar Fantastic Call Girls-9833754194-Call Girls MUmbaiVasai-Virar Fantastic Call Girls-9833754194-Call Girls MUmbai
Vasai-Virar Fantastic Call Girls-9833754194-Call Girls MUmbai
 
(Sexy Sheela) Call Girl Mumbai Call Now 👉9920725232👈 Mumbai Escorts 24x7
(Sexy Sheela) Call Girl Mumbai Call Now 👉9920725232👈 Mumbai Escorts 24x7(Sexy Sheela) Call Girl Mumbai Call Now 👉9920725232👈 Mumbai Escorts 24x7
(Sexy Sheela) Call Girl Mumbai Call Now 👉9920725232👈 Mumbai Escorts 24x7
 
Cybersecurity Threats in Financial Services Protection.pptx
Cybersecurity Threats in  Financial Services Protection.pptxCybersecurity Threats in  Financial Services Protection.pptx
Cybersecurity Threats in Financial Services Protection.pptx
 
VIP Independent Call Girls in Mira Bhayandar 🌹 9920725232 ( Call Me ) Mumbai ...
VIP Independent Call Girls in Mira Bhayandar 🌹 9920725232 ( Call Me ) Mumbai ...VIP Independent Call Girls in Mira Bhayandar 🌹 9920725232 ( Call Me ) Mumbai ...
VIP Independent Call Girls in Mira Bhayandar 🌹 9920725232 ( Call Me ) Mumbai ...
 
➥🔝 7737669865 🔝▻ Malda Call-girls in Women Seeking Men 🔝Malda🔝 Escorts Ser...
➥🔝 7737669865 🔝▻ Malda Call-girls in Women Seeking Men  🔝Malda🔝   Escorts Ser...➥🔝 7737669865 🔝▻ Malda Call-girls in Women Seeking Men  🔝Malda🔝   Escorts Ser...
➥🔝 7737669865 🔝▻ Malda Call-girls in Women Seeking Men 🔝Malda🔝 Escorts Ser...
 
Pension dashboards forum 1 May 2024 (1).pdf
Pension dashboards forum 1 May 2024 (1).pdfPension dashboards forum 1 May 2024 (1).pdf
Pension dashboards forum 1 May 2024 (1).pdf
 
Q1 2024 Conference Call Presentation vF.pdf
Q1 2024 Conference Call Presentation vF.pdfQ1 2024 Conference Call Presentation vF.pdf
Q1 2024 Conference Call Presentation vF.pdf
 
Call Girls Banaswadi Just Call 👗 7737669865 👗 Top Class Call Girl Service Ban...
Call Girls Banaswadi Just Call 👗 7737669865 👗 Top Class Call Girl Service Ban...Call Girls Banaswadi Just Call 👗 7737669865 👗 Top Class Call Girl Service Ban...
Call Girls Banaswadi Just Call 👗 7737669865 👗 Top Class Call Girl Service Ban...
 
20240419-SMC-submission-Annual-Superannuation-Performance-Test-–-design-optio...
20240419-SMC-submission-Annual-Superannuation-Performance-Test-–-design-optio...20240419-SMC-submission-Annual-Superannuation-Performance-Test-–-design-optio...
20240419-SMC-submission-Annual-Superannuation-Performance-Test-–-design-optio...
 
Strategic Resources May 2024 Corporate Presentation
Strategic Resources May 2024 Corporate PresentationStrategic Resources May 2024 Corporate Presentation
Strategic Resources May 2024 Corporate Presentation
 
VIP Call Girl Service Andheri West ⚡ 9920725232 What It Takes To Be The Best ...
VIP Call Girl Service Andheri West ⚡ 9920725232 What It Takes To Be The Best ...VIP Call Girl Service Andheri West ⚡ 9920725232 What It Takes To Be The Best ...
VIP Call Girl Service Andheri West ⚡ 9920725232 What It Takes To Be The Best ...
 
VIP Independent Call Girls in Bandra West 🌹 9920725232 ( Call Me ) Mumbai Esc...
VIP Independent Call Girls in Bandra West 🌹 9920725232 ( Call Me ) Mumbai Esc...VIP Independent Call Girls in Bandra West 🌹 9920725232 ( Call Me ) Mumbai Esc...
VIP Independent Call Girls in Bandra West 🌹 9920725232 ( Call Me ) Mumbai Esc...
 
W.D. Gann Theory Complete Information.pdf
W.D. Gann Theory Complete Information.pdfW.D. Gann Theory Complete Information.pdf
W.D. Gann Theory Complete Information.pdf
 
VIP Independent Call Girls in Taloja 🌹 9920725232 ( Call Me ) Mumbai Escorts ...
VIP Independent Call Girls in Taloja 🌹 9920725232 ( Call Me ) Mumbai Escorts ...VIP Independent Call Girls in Taloja 🌹 9920725232 ( Call Me ) Mumbai Escorts ...
VIP Independent Call Girls in Taloja 🌹 9920725232 ( Call Me ) Mumbai Escorts ...
 
7 tips trading Deriv Accumulator Options
7 tips trading Deriv Accumulator Options7 tips trading Deriv Accumulator Options
7 tips trading Deriv Accumulator Options
 

Persistent Systems Q1FY15: Soft performance, margin headwinds limit near term upside

  • 1.     Persistent Systems  Soft performance, Margin headwinds limit near term upside July 28, 2014  Prabhudas Lilladher Pvt. Ltd. and/or its associates (the 'Firm') does and/or seeks to do business with companies covered in its research reports. As a result investors should be aware that  the Firm may have a conflict of interest that could affect the objectivity of the report. Investors should consider this report as only a single factor in making their investment decision.  Please refer to important disclosures and disclaimers at the end of the report    Q1FY15 Result Update  Shashi Bhusan  shashibhusan@plindia.com  +91‐22‐66322300  Hussain Kagzi  hussainkagzi@plindia.com  +91‐22‐66322242  Rating  Accumlate  Price  Rs1,284  Target Price  Rs1,285  Implied Upside   .1%  Sensex   26,127  Nifty  7,790  (Prices as on July 25, 2014)  Trading data  Market Cap. (Rs bn)  51.4  Shares o/s (m)  40.0  3M Avg. Daily value (Rs m)  222.4  Major shareholders  Promoters   38.96%  Foreign   27.37%  Domestic Inst.  9.82%  Public & Other   23.85%  Stock Performance   (%)  1M  6M  12M  Absolute  16.0  27.4  138.8  Relative   12.8  3.7  106.9  How we differ from Consensus  EPS (Rs)  PL  Cons.  % Diff.  2015  78.6  77.7  1.2  2016  94.2  90.8  3.8    Price Performance (RIC: PERS.BO, BB: PSYS IN)    Source: Bloomberg  0 200 400 600 800 1,000 1,200 1,400 1,600 Jul‐13 Sep‐13 Nov‐13 Jan‐14 Mar‐14 May‐14 Jul‐14 (Rs) Persistent Systems’ (Persistent’s) Q1FY15 result was another soft quarter compared  to  PLe/Consensus’  expectation.  We  see  weak  start  to  the  year  and  near  term  headwinds to operating margin to restrict upside. Retain “Accumulate”.    Revenue  and  margin  softer  than  expected:  Persistent’s  Q1FY15  result  was  softer  than  expectation.  Revenue  declined  by  2.6%  QoQ  to  Rs4,349.9m  (PLe:  Rs4,384m  Cons:  Rs4,385m)  and  flattish  in  USD  terms  to  US$72.66m  (PLe:  US$73.4m, Cons: US$73.4m). EBITDA margins eroded by 519bps to 21.8% (PLe:  24%, Cons: 24%) due to higher S&M cost (investment and wage hike ~7%), and  currency  appreciation.  EPS  grew  by  2.4%  QoQ  to  Rs17.2  (PLe:  Rs17.2,  Cons:  Rs16.8) due to forex gain of Rs133m (Q4FY14 loss of Rs87mn).    IP  had  better  than  seasonal  quarter,  client  addition  strong:  IP  revenue  for  Q1FY15 tracked better than seasonality expectation. The growth outlook for IP  in  FY15  continues  to  be  strong.  The  investment  in  sales  and  marketing  has  started  showing  early  traction  with  76  new  clients’  addition  in  Q1FY15.  The  management continues to hold the view of stronger FY15 than FY14.    S&M  investment  and  wage  hike  –  Margin  headwinds:  The  management  continues to invest in S&M team expanding their workforce by 52 QoQ (18 new  additions and rest reclassification of account managers as S&M that was earlier  classified in technical) to 202. We believe S&M investment, which will continue  through FY15, is right strategic move as Persistent gears up for enterprise sales.  Moreover,  the  wage  hike  for  technical  workforce  would  be  headwind  to  the  margin in Q2FY15. However, non‐recurring visa cost, room for higher utilization,  and seasonally strong IP‐revenue would give margin tailwind in FY15.   Valuation & Recommendation: Persistent has delivered the margin and revenue  performance in FY14, but heightened consensus expectation leave limited scope  for earnings upgrade. However, the constant pursuits to inorganic opportunity  leave  room  for  surprises.  Despite,  high‐teen  revenue  performance,  margin  headwinds  would yield decelerated  earnings  growth.  We Retain  ‘Accumulate’  with revised target price of Rs1,285 (Old: Rs1,130).        Key financials (Y/e March)    2013 2014  2015E 2016E Revenues (Rs m)  12,945 16,692  19,228 22,745      Growth (%)  29.4 28.9  15.2 18.3 EBITDA (Rs m)  3,352 4,303  4,885 5,746 PAT (Rs m)  1,876 2,493  3,144 3,770 EPS (Rs)  46.9 62.3  78.6 94.2      Growth (%)  32.3 32.9  26.1 19.9 Net DPS (Rs)  8.5 11.3  13.2 15.1   Profitability & Valuation    2013 2014  2015E 2016E EBITDA margin (%)  25.9 25.8  25.4 25.3 RoE (%)  20.2 22.3  23.2 23.0 RoCE (%)  19.4 21.7  22.4 22.4 EV / sales (x)  4.0 3.0  2.6 2.2 EV / EBITDA (x)  15.4 11.8  10.3 8.6 PE (x)  27.4 20.6  16.3 13.6 P / BV (x)  5.0 4.2  3.5 2.9 Net dividend yield (%)  0.7 0.9  1.0 1.2 Source: Company Data; PL Research 
  • 2.     July 28, 2014  2   Persistent Systems  Exhibit 1: Revenue and margin lower than expected (Rs m)  Y/e March  Q1FY15  Q4FY14  QoQ Q1FY14 YoY Cons  PLe Var (Act. Vs Est.) Sales ($ m)   72.7   72.6  0.0%  63.0  15.3%  73.4   73.4  ‐1.0% Period Average Rate   59.87   61.50  ‐2.7%  56.7  5.6%  59.7   59.7  Sales   4,349.9   4,467  ‐2.6%  3,572.9  21.7%  4,385.0   4,383.7  ‐0.8%    EBITDA   949.0   1,206.5  ‐21.3%  776.9  22.1%  1,053.0   1,052.1  ‐9.8% EBITDA Margin  21.8%  27.0%  ‐519 bps 21.7% 7 bps 24.0%  24.0% ‐218 bps    PBT    954.2   923.3  3.3%  803.1  18.8%  944.0   947.2  0.7% Tax   266.1  251.3  5.9% 232.2 14.6%  268.3  255.7 4.1%   Tax Rate  27.9%  27.2%  67 bps 28.9% ‐102 bps 28.4%  27.0% 89 bps    PAT   688.0   672.0  2.4%  571.0  20.5%  675.7   691.5  ‐0.5% EPS (Rs)   17.2   16.7  2.9%  14.2  21.1%  16.8   17.2  0.0% Source: Company Data, Bloomberg, PL Research  Exhibit 2: S&M investment continues – Continues ramping‐up the sales team     Q1FY15 Q4FY14  QoQ  Q1FY14 YoY Sales & Business Development  202   150  34.7%   119  69.7% S&M Expense   389   342  13.9%   319  21.8% S&M (% of Revs)  8.9% 7.6%  129 bps  8.9% 1 bps Source: Company Data, PL Research  Exhibit 3: Strong growth in America and Europe  By Geography ($m)  Q1FY15 Q4FY14  QoQ  Q1FY14 YoY America   62.4   62.0  0.6%   55.2  13.0% Europe   4.7   4.4  6.6%   3.0  56.1% RoW   5.5   6.2  ‐10.6%   4.8  15.3%    % of Total  America  85.9% 85.4%  50 bps  87.6% ‐170 bps Europe  6.5% 6.1%  40 bps  4.8% 170 bps Row  7.6% 8.5%  ‐90 bps  7.6% 0 bps Source: Company Data, PL Research 
  • 3.     July 28, 2014  3   Persistent Systems  Exhibit 4: Strong growth in Telecom   By Vertical Offering ($ m)  Q1FY15 Q4FY14  QoQ  Q1FY14 YoY Telecom   13.4   11.1  20.9%   13.0  3.0% Infrastructure and BFSI   49.7   52.0  ‐4.4%   43.6  14.1% Life Sciences & Healthcare   9.5   9.5  0.0%   6.4  48.1%    % of Total  Telecom  18.5% 15.3%  320 bps  20.7% ‐220 bps Infrastructure and Systems  68.4% 71.6%  ‐320 bps  69.1% ‐70 bps Life Sciences & BFSI  13.1% 13.1%  0 bps  10.2% 290 bps Source: Company Data, PL Research  Exhibit 5: Pricing likely to remain stable at this level, Yield flattish  Delivery Split  Q1FY15 Q4FY14  QoQ  Q1FY14 YoY Onsite   16.8   15.5  8.0%   13.4  25.6% Offshore   41.3   42.9  ‐3.5%   40.2  3.0% IP Driven   14.5   14.2  2.1%   9.5  52.7%    Fee Revenue  Onsite  23.1% 21.4%  170 bps  21.2% 190 bps Offshore  56.9% 59.0%  ‐210 bps  63.7% ‐680 bps IP Driven  20.0% 19.6%  40 bps  15.1% 490 bps    Pricing (USD/ person month) Onsite   14,905   14,355  3.8%   14,567  2.3% Offshore   4,219   4,241  ‐0.5%   4,111  2.6% Yield  3915.0 3927.0  ‐0.3%  3602.0 8.7% Source: Company Data, PL Research  Exhibit 6: IP‐led revenue strong despite seasonality  By Business Offering ($ m)  Q1FY15 Q4FY14  QoQ  Q1FY14 YoY Product Engineering & Platform  58.1   58.4  ‐0.5%   53.5  8.6% IP Led   14.5   14.2  2.1%   9.5  52.7%    % of Total  Product Engineering & Platform 80.0% 80.4%  ‐40 bps  84.9% ‐490 bps IP Led  20.0% 19.6%  40 bps  15.1% 490 bps Source: Company Data, PL Research 
  • 4.     July 28, 2014  4   Persistent Systems  Exhibit 7: Attrition up in‐line with industry  Manpower details  Q1FY15 Q4FY14  QoQ  Q1FY14 YoY Billable   16,139   16,155  ‐0.1%   15,161  6.5% Billed   10,925   11,183  ‐2.3%   10,607  3.0% IP Led   2,419   2,343  3.2%   2,335  3.6% Sales & Business Development  202  150  34.7%  119 69.7% Support   403  358  12.6%  336 19.9% Technical   7,271   7,349  ‐1.1%   6,689  8.7% Total   7,876   7,857  0.2%   7,144  10.2% DSO   69   63  9.5%   65  6.2% Attrition (LTM)  14.0% 13.4%  60 bps  14.2% ‐20 bps Source: Company Data, PL Research  Exhibit 8: Weak growth from top 5 clients  Client Details  Q1FY15 Q4FY14  QoQ  Q1FY14 YoY Large > $ 3m   14   15  ‐6.7%   15  ‐6.7% Medium > $ 1m, < $ 3m   38   36  5.6%   30  26.7% Prod. Eng. & Platforms   260   261  ‐0.4%   253  2.8% IP Led   347   358  ‐3.1%   387  ‐10.3%    Top Client   15.1   15.3  ‐1.4%   13.4  13.1% Top 2‐5 Clients   13.0   13.3  ‐2.2%   9.6  35.8% Top 5 Clients   28.1   28.6  ‐1.7%   22.9  22.6% Top 6‐10 Clients   7.5   6.6  13.2%   6.9  8.9% Top 10 Clients   35.6   35.2  1.1%   29.8  19.4% Non Top 10 Clients   37.1   37.4  ‐0.9%   33.2  11.6%    % of Total  Top Client  20.8% 21.1%  ‐30 bps  21.2% ‐40 bps Top 5 Clients  38.7% 39.4%  ‐70 bps  36.4% 230 bps Top 10 Clients  49.0% 48.5%  50 bps  47.3% 170 bps Non Top 10 Clients  51.0% 51.5%  ‐50 bps  52.7% ‐170 bps    Revenue from repeat business  63.0   61.9  1.8%   52.3  20.4% Non‐repeat business   9.7   10.8  ‐10.1%   10.7  ‐9.8%    % of Total  New Business  13.3% 14.8%  ‐150 bps  17.0% ‐370 bps Repeat Business  86.7% 85.2%  150 bps  83.0% 370 bps Source: Company Data, PL Research       
  • 5.     July 28, 2014  5   Persistent Systems  Income Statement (Rs m)            Y/e March   2013  2014  2015E 2016E Net Revenue  12,945  16,692  19,228 22,745 Raw Material Expenses  —  —  — — Gross Profit  12,945  16,692  19,228 22,745 Employee Cost  8,888  11,406  13,192 15,679 Other Expenses  705  983  1,151 1,319 EBITDA  3,352  4,303  4,885 5,746 Depr. & Amortization  783  1,026  1,007 1,180 Net Interest  —  78  (21) 1 Other Income  61  228  468 529 Profit before Tax  2,630  3,427  4,367 5,094 Total Tax  754  934  1,223 1,324 Profit after Tax  1,876  2,493  3,144 3,770 Ex‐Od items / Min. Int.  —  —  — — Adj. PAT  1,876  2,493  3,144 3,770 Avg. Shares O/S (m)  40.0  40.0  40.0 40.0 EPS (Rs.)  46.9  62.3  78.6 94.2   Cash Flow Abstract (Rs m)     Y/e March     2013  2014  2015E 2016E C/F from Operations  2,163  2,808  3,592 4,242 C/F from Investing  (1,711)  (1,958)  (2,307) (2,729) C/F from Financing  (386)  (516)  (404) (603) Inc. / Dec. in Cash  66  334  881 910 Opening Cash  433  499  833 1,714 Closing Cash  499  833  1,714 2,624 FCFF  1,352  1,789  1,285 1,513 FCFE  1,928  1,561  1,285 1,513       Key Financial Metrics  Y/e March             2013  2014  2015E 2016E Growth      Revenue (%)  29.4  28.9  15.2 18.3 EBITDA (%)  44.2  28.4  13.5 17.6 PAT (%)  32.3  32.9  26.1 19.9 EPS (%)  32.3  32.9  26.1 19.9 Profitability      EBITDA Margin (%)  25.9  25.8  25.4 25.3 PAT Margin (%)  14.5  14.9  16.4 16.6 RoCE (%)  19.4  21.7  22.4 22.4 RoE (%)  20.2  22.3  23.2 23.0 Balance Sheet      Net Debt : Equity  —  —  (0.1) (0.1) Net Wrkng Cap. (days)  —  —  — — Valuation      PER (x)  27.4  20.6  16.3 13.6 P / B (x)  5.0  4.2  3.5 2.9 EV / EBITDA (x)  15.4  11.8  10.3 8.6 EV / Sales (x)  4.0  3.0  2.6 2.2 Earnings Quality      Eff. Tax Rate  28.7  27.3  28.0 26.0 Other Inc / PBT  2.3  6.7  10.7 10.4 Eff. Depr. Rate (%)  11.3  12.0  9.3 8.7 FCFE / PAT  102.8  62.6  40.9 40.1 Source: Company Data, PL Research.        Balance Sheet Abstract (Rs m)    Y/e March      2013  2014  2015E 2016E Shareholder's Funds  10,183  12,223  14,840 18,006 Total Debt  653  426  426 426 Other Liabilities  —  —  — — Total Liabilities  10,836  12,649  15,266 18,432 Net Fixed Assets  4,677  4,362  5,662 7,212 Goodwill  721  620  620 620 Investments  3,289  4,895  4,895 4,895 Net Current Assets  1,959  2,512  3,829 5,445      Cash & Equivalents  561  957  1,714 2,624      Other Current Assets  3,291  4,340  5,151 6,392      Current Liabilities  1,894  2,785  3,037 3,570 Other Assets  190  260  260 260 Total Assets  10,836  12,649  15,266 18,432         Quarterly Financials (Rs m)      Y/e March      Q2FY14  Q3FY14  Q4FY14 Q1FY15 Net Revenue  4,324  4,328  4,467 4,350 EBITDA  1,122  1,197  1,207 949 % of revenue  26.0  27.7  27.0 21.8 Depr. & Amortization  263  262  264 228 Net Interest  (75)  147  87 (133) Other Income  (100)  77  68 100 Profit before Tax  835  865  923 954 Total Tax  227  223  251 266 Profit after Tax  608  642  672 688 Adj. PAT  608  642  672 688   Key Operating Metrics  Y/e March       2013  2014 2015E 2016E Volume (persons month)  41,176  44,033 50,638 59,246 Realization (US$ / person month)  3,686  3,847 3,905 3,998 Currency (USDINR)  54.5  60.9 59.8 59.0 SW Devp. Cost (% of sales)  68.7  68.3 68.6 68.9 SG&A (% of sales)  5.4  5.9 6.0 5.8 Revenue (US$ m)  237.8  275.7 321.8 385.5 EBITDA Margin Expansion/(Erosion) (bps)  0.7  (1.4) 75.0 (200.0) Tax Rate (%)  28.7  27.3 28.0 26.0 Source: Company Data, PL Research.   
  • 6.     July 28, 2014  6   Persistent Systems            Prabhudas Lilladher Pvt. Ltd.  3rd Floor, Sadhana House, 570, P. B. Marg, Worli, Mumbai‐400 018, India  Tel: (91 22) 6632 2222 Fax: (91 22) 6632 2209  Rating Distribution of Research Coverage    29.6% 50.9% 19.4% 0.0% 0% 10% 20% 30% 40% 50% 60% BUY Accumulate Reduce Sell % of Total Coverage   PL’s Recommendation Nomenclature      BUY   :  Over 15% Outperformance to Sensex over 12‐months  Accumulate  :  Outperformance to Sensex over 12‐months  Reduce  :  Underperformance to Sensex over 12‐months  Sell  :  Over 15% underperformance to Sensex over 12‐months  Trading Buy  :  Over 10% absolute upside in 1‐month  Trading Sell  :  Over 10% absolute decline in 1‐month  Not Rated (NR)  :  No specific call on the stock  Under Review (UR)  :  Rating likely to change shortly  This  document  has  been  prepared  by  the  Research  Division  of  Prabhudas  Lilladher  Pvt.  Ltd.  Mumbai,  India  (PL)  and  is  meant  for  use  by  the  recipient  only  as  information and is not for circulation.  This document is not to be reported or copied or made available to others without prior permission of PL. It should not be  considered or taken as an offer to sell or a solicitation to buy or sell any security.  The information contained in this report has been obtained from sources that are considered to be reliable. However, PL has not independently verified the accuracy  or completeness of the same. Neither PL nor any of its affiliates, its directors or its employees accept any responsibility of whatsoever nature for the information,  statements and opinion given, made available or expressed herein or for any omission therein.  Recipients of this report should be aware that past performance is not necessarily a guide to future performance and value of investments can go down as well. The  suitability  or  otherwise  of  any  investments  will  depend  upon  the  recipient's  particular  circumstances  and,  in  case  of  doubt,  advice  should  be  sought  from  an  independent expert/advisor.  Either PL or its affiliates or its directors or its employees or its representatives or its clients or their relatives may have position(s), make market, act as principal or  engage in transactions of securities of companies referred to in this report and they may have used the research material prior to publication.  We may from time to time solicit or perform investment banking or other services for any company mentioned in this document.